Pedro Vilarinho Pires on the decision that may exclude Huawei from 5G | Observador

A flawed judgment on a problem that has remained unresolved to date in the truck cartel. The issue is not whether the liability-in-solidum regime applies, but whether co-liable parties can raise personal defences.

The Supreme Court and the Madrid Provincial Court, following established legal doctrine, have reiterated that a party to a unanimous shareholders’ agreement acts in bad faith if he or she challenges a company resolution passed in compliance with said shareholders’ agreement. In this case, the shareholders’ agreement provided for the possibility of paying dividends in kind, and the contested resolution — which was passed by a majority at the shareholders’ meeting — transferred certain real estate properties to one of the shareholders (with his consent) in payment of the dividend due to him.

An action for declaration of invalidity of an agreement can almost always be brought, even if the agreement has been performed and terminated.

This paper examines the recent judgment of the Court of Justice of 14 April 2026, Pelham (C-590/23, ECLI:EU:C:2026:290), which interprets the exception for pastiche contained in Directive 2001/29/EC of the European Parliament and of the Council of 22 May 2001 on the harmonisation of certain aspects of copyright and related rights in the information society.

The newsletter covers the main developments in Pharma & Healthcare legislation and case law.

The State Secretariat for Telecommunications and Digital Infrastructures has published, on 14 April 2016, two decisions: one allocating public numbering resources to customer service and laying down the general terms of use thereof, and the other allocating public numbering resources to telemarketing and laying down the general terms of use thereof.

The newsletter covers the main developments in Pharma & Healthcare legislation and case law.

The protocol, agreed jointly by the Courts of Barcelona and Alicante, provides for priority handling of applications for pre-trial examination and fact-finding orders, as well as applications for interim measures —with or without a hearing— in matters relating to patents and technological innovations, industrial designs, trademarks and copyright, as well as antitrust, unfair competition and unlawful advertising, when linked to products or presentation, display, promotion, offering or sale activities connected to MWC 2026.

The newsletter covers the main developments in Pharma & Healthcare legislation and case law.